GMP BIO CO., LTD.

닫기

PIPELINE

Alzhimer's anti-dementia drugs (VT301, VT012)

Background

Multinational pharmaceutical companies have given up on developing dementia therapy, citing financial burdens and low chances of success, So far, there's been no drugs for the cure for dementia, No new drugs have been approved by the FDA since 2003.

Announcement of the government's plan to push for a "National Responsibility for Dementia" that will spend 1.01 trillion won on research and development related to dementia between 2020 and 2029.

Market

The global market for dementia drugs is estimated at 12.61 billion dollars in 2024.

The number of dementia patients in Korea exceeded 600,000, The forecast dementia 1 million people in 2025., 2 million peoplein 2043 and 100 million people in 2050. (Ministry of Health and Welfare)

R&D

VT301 is about the formation of a degenerative brain disease prevention or treatment cellular therapy with the efficacy of regulatory T cells, personalization kits, and the phase in which these compounds are administered to degenerative brain disease objects.

VT012 is effective in the Yukmijihwangtang-gagambang(YMG), which is a prescription for anti-dementia drugs, and succeeded in pharmaceuticalization by extracting active materials that enhance the expression of a specific gene.

Demonstrate that amyloid beta accumulates and can improve Alzheimer's-type dementia, which destroys nerve cells, Registered in SCI journal (Molecular Neurobiology: Standardized Herbal Formula VT012 Decreases Cognitive Impairment and Promotes Neurogenesis in the 3xTg AD Mouse Model of Alzheimer’s Disease)

VT012 shows 40% better ability to improve Amyloid beta composure than conventional synthetic anti-dementia drug, 20% better in spatial recognition testing, and 30% better nerve regeneration capability

Pipeline
Overview
Classification PIPELINE Candidate material Preclinical Clinical New Drug approval Item permit
1 2 3
Cell therapy
(*Treg cell)
Alzhimer's
disease
(VT301)
  • Technology transfer completed (Kyung Hee University)
  • Domestic GLP Specialized Companies Chemon Complete preclinical
  • Australian clinical 1/2a phase scheduled at the same time
Natural
product medicine
(VT012)
  • Clinical 2-phase complete (MFDS)
  • Clinical 3-phase IND

Preparation for approval of new drugs and items with domestic pharmaceutical companies (clinical 3-phase IND)

When entering the market with existing pharmaceutical companies, approval of their own products and marketing strategies are possible through entering the pharmaceutical companies

Thesis
  • Mol Neurobiol. 2016 Oct;53(8):5401-12 (IF: 6.190)

    Standardized Herbal Formula PM012 Decreases Cognitive Impairment and Promotes Neurogenesis in the 3xTg AD Mouse Model of Alzheimer’s Disease

  • Brain Behav Immun. 2012 Nov;26(8):1322-30 (IF: 5.964)

    Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: Role of regulatory T cells

  • Oncotarget. 2016 Oct 25;7(43):69347-69357 (IF: 5.102)

    Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model

  • Am J Chin Med. 2005;33(1):107-15 (IF: 3.222)

    Yukmijihwang-tang derivatives enhance cognitive processing in normal young adults: a double-blinded, placebo-controlled trial

  • BMC Complement Altern Med. 2012 Mar 29;12:24 (IF: 2.981)

    Safety and efficacy assessment of standardized herbal formula PM012

  • Evid Based Complement Alternat Med. 2013;2013:542081 (IF: 1.740)

    The neuroprotective effect of gugijihwang-tang on trimethyltin-induced memory dysfunction in the rat

  • Biol Pharm Bull. 2006 Jul;29(7):1431-5 (IF: 1.683)

    Effects of Yukmijihwang-tang Derivatives (YMJd) on Ibotenic Acid-Induced Amnesia in the Rat

  • Biol Pharm Bull. 2005 Jan;28(1):87-93 (IF: 1.683)

    Effects of Yukmijihwang-tang derivatives (YMJd), a memory enhancing herbal extract, on the gene-expression profile in the rat hippocampus

  • Biol Pharm Bull. 2005 Apr;28(4):661-6 (IF: 1.683)

    Inhibition of production of reactive oxygen species and gene expression profile by treatment of ethanol extract of Moutan Cortex Radicis in oxidative stressed PC12 cells

Patent

Memory-enhanced herb medicine composition including Rehmanniae Radix Preparata extracts (Registration number: 1005000290000, Registration date: 2005.06.29)

Performance task

A Study on the Development of Oriental Medicine Technology (IND approval and development of anti-dementia agent using Gugijihwang-Tang, The Ministry of Health and Welfare, 2008)

알츠하이머 항치매제 (PM012) 예시 이미지
top